Call now 828.375.0145
  • CYP2C19 enzyme catalyzes the bioactivation of the antiplatelet prodrug, clopidogrel. Patients who are CYP2C19 poor metabolizers may have diminished effectiveness of the drug, leading to higher cardiovascular event rates following acute coronary syndrome or percutaneous coronary intervention, as compared to patients with normal CYP2C19 function.